DURECT Corp (DRRX) Reports In-Line Q2 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St mixed as benchmark Treasury yields reach 5%, oil takes a pause
- Oil slides following outreach to Iran to limit Houthis actions in Red Sea
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
DURECT Corporation Announces Second Quarter 2021 Financial Results and Update of Programs
July 29, 2021 4:05 PM EDTCUPERTINO, Calif., July 29, 2021 /PRNewswire/ --Â DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended June 30, 2021 and provided a corporate update.
Q2 2021 Accomplishments:
We expanded the number of U.S. clinical trial sites to 26 in the Phase 2b AHFIRM clinical study of DUR-928 in severe alcohol-associated hepatitis (AH), and... More
